These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 18194172

  • 1. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, Sjogren M, Farmer D, Ramsey L, Terra K, Gujral H, Gurung C, Srishord M, Fang Y.
    J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
    [Abstract] [Full Text] [Related]

  • 2. Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
    Pau AK, McLaughlin MM, Hu Z, Agyemang AF, Polis MA, Kottilil S.
    AIDS Patient Care STDS; 2006 Sep; 20(9):612-9. PubMed ID: 16987047
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S, Asensi V, Barreiro P, Garcia-Samaniego J, Soriano V, PRESCO Team.
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [Abstract] [Full Text] [Related]

  • 6. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
    Bräu N.
    J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
    Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM.
    J Acquir Immune Defic Syndr; 2011 Nov 01; 58(3):261-8. PubMed ID: 21876446
    [Abstract] [Full Text] [Related]

  • 8. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Collantes RS, Younossi ZM.
    J Clin Gastroenterol; 2005 Jan 01; 39(1 Suppl):S9-13. PubMed ID: 15597026
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep 01; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
    Wikman Jorgensen PE, Jover Díaz FM, Cuadrado Pastor JM.
    Gastroenterol Hepatol; 2007 Apr 01; 30(4):253. PubMed ID: 17408558
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.
    Sharvadze L, Gochitashvili N, Tophuria A, Bolokadze N, Tsertsvadze T.
    Georgian Med News; 2007 Jun 01; (147):52-5. PubMed ID: 17660602
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May 01; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
    Del Rio RA, Post AB, Singer ME.
    Hepatology; 2006 Dec 01; 44(6):1598-606. PubMed ID: 17133490
    [Abstract] [Full Text] [Related]

  • 17. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
    Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P.
    Ann Hematol; 2013 May 01; 92(5):621-31. PubMed ID: 23358617
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E, Wade JR, Duff F, Lamb M, Jorga K.
    Br J Clin Pharmacol; 2006 Dec 01; 62(6):699-709. PubMed ID: 17118125
    [Abstract] [Full Text] [Related]

  • 20. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
    Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ, Proactive Study Group.
    Gastroenterology; 2004 May 01; 126(5):1302-11. PubMed ID: 15131791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.